FDA ARC Program Advances Bayesian Trial Design and Biomarker Tools for Rare Disease Submissions

CDER's Accelerating Rare Disease Cures (ARC) Program is expanding the methodological toolkit available to sponsors navigating small-population drug development, with externally funded research contracts targeting trial design efficiency and disease-specific biomarker validation, two persistent friction points in rare disease regulatory submissions.

Through its Broad Agency Announcement (BAA) research contracts, ARC's Rare Diseases Team (RDT) is funding two active external projects. The first, conducted with the University of Michigan Department of Biostatistics, applies multicomponent endpoints, interim analyses, and Bayesian joint modeling to improve clinical trial design for small samples intended to support 21 CFR Part 312-compliant regulatory submissions. For statisticians and clinical operations leads working under ICH E9(R1) addendum requirements, the practical output is a more defensible analytical framework when powering trials with limited patient populations.

The second contract, led by Wake Forest University and the Critical Path Institute, focuses on Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD). The project ingests and curates phenotyping data from the Wake Forest ADTKD patient registry, then builds disease progression models incorporating fluid and imaging biomarker covariates. Validated biomarker endpoints derived from this work could eventually qualify as Drug Development Tools under FDA's DDT qualification program, reducing evidentiary burden for future ADTKD sponsors at the IND and NDA stages.

Internally, ARC and the RDT also support research conducted by FDA staff and ORISE fellows. One completed internal project examined pivotal trial characteristics underlying rare disease drug approvals between 2013 and 2022, providing the agency with a structured evidence base for refining review standards and guidance development across therapeutic areas.

For regulatory affairs leads and QA directors, the operational read is direct: methodologies validated through ARC-funded contracts are likely to inform future CDER guidance and review expectations for rare disease programs. Sponsors building statistical analysis plans or biomarker qualification packages for small-population indications should track ARC publications as leading indicators of acceptable methodology.

The ADTKD biomarker work has already generated six peer-reviewed publications between 2024 and 2025, signaling a pace of evidence generation that could accelerate DDT qualification timelines for this indication.

Source: FDA CDER ARC Program via FDA.gov, May 14, 2026.